Many clinical trials have been launched to test the efficacy of mTOR inhibitors as single agents, particularly in the treatment of relapsed hematological diseases (eg. everolimus for relapsed/refractory NHL – phase I; sirolimus for relapsed/refractory ALL/NHL – phase I) [33]. This evidence concerns the gene MTOR and hematologic disorder.